<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01233648</url>
  </required_header>
  <id_info>
    <org_study_id>0601113</org_study_id>
    <nct_id>NCT01233648</nct_id>
  </id_info>
  <brief_title>Resync-AF (Rate vs Rhythm Control in AF Patients With CRT-D)</brief_title>
  <official_title>Resync-AF (Rate vs Rhythm Control in AF Patients With CRT-D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <brief_summary>
    <textblock>
      This study is being done to find out if controlling rate or controlling rhythm is better for&#xD;
      heart failure patients who also have AF. Patients with AF who are receiving a CRT-D device&#xD;
      and AV node ablation as part of their clinical care will be followed for one year. One group&#xD;
      will have their heart rate controlled by the ICD and AVN ablation alone and the second group&#xD;
      will be treated with the ICD, AVN ablation and standard medical therapies to restore the&#xD;
      heart's normal rhythm. The study doctors will compare the information collected from all of&#xD;
      the subjects in this study to see if treating rate or treating rhythm is better in patients&#xD;
      with heart failure and AF, resulting in a better quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AF burden</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>AF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>rate control via CRT-D and AVN ablation</intervention_name>
    <description>rate control</description>
    <arm_group_label>AF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>rhythm control via pharmacologic, electrical or ablative therapies</intervention_name>
    <description>rhythm control</description>
    <arm_group_label>SR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having persistent AF, defined as AF that does not self terminate for at least 24&#xD;
             consecutive hours.&#xD;
&#xD;
          -  In AF upon entry into the operating room for CRT-D implantation and AV node ablation.&#xD;
&#xD;
          -  Being on a stable dosage of an ACE inhibitor or ARB for at least 1 month preceding&#xD;
             implant&#xD;
&#xD;
          -  Being on a Beta-blocker for at least 3 months preceding implant and a stable dosage&#xD;
             within 1 month of implant&#xD;
&#xD;
          -  Not taking or able to be taken off all type I/III antiarrhythmic medications.&#xD;
&#xD;
          -  Taking Coumadin so as to maintain an INR of between 2 and 3.&#xD;
&#xD;
          -  A Class I or IIa ICD indication&#xD;
&#xD;
          -  NYHA Class III/IV within 1 month of baseline&#xD;
&#xD;
          -  Intrinsic QRS duration ≥ 130 ms within 1 month prior to baseline&#xD;
&#xD;
          -  Left ventricular ejection fraction ≤ 35% (method per physician discretion) within 1&#xD;
             month prior to baseline&#xD;
&#xD;
          -  Left ventricular end diastolic dimension (LVEDD) ≥ 55 mm (method per physician&#xD;
             discretion) within 1 months prior to baseline&#xD;
&#xD;
          -  Willing to provide written informed consent&#xD;
&#xD;
          -  Are expected to survive for 6 month of study participation&#xD;
&#xD;
          -  Able to tolerate an urgent thoracotomy&#xD;
&#xD;
          -  Able to tolerate &lt; 1 mg dexamethasone sodium phosphate (steroid)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Having self-terminating or interminable AF&#xD;
&#xD;
          -  Having unstable angina, or having experienced an acute myocardial infarction (MI) or&#xD;
             received coronary artery revascularization (CABG) or coronary angioplasty (PTCA)&#xD;
             within the past 1 month&#xD;
&#xD;
          -  Post-heart transplant (patients on heart transplant list for the first time are not&#xD;
             excluded)&#xD;
&#xD;
          -  Having mechanical right heart valve&#xD;
&#xD;
          -  Having an existing CRT or atrial therapy device(s)&#xD;
&#xD;
          -  Being enrolled in any concurrent drug and/or device study which would confound the&#xD;
             results of this trial&#xD;
&#xD;
          -  Having primary valvular disease and indicated for valve repair or replacement&#xD;
&#xD;
          -  Having a previous AV node ablation&#xD;
&#xD;
          -  Being on a Type I or Type III anti-arrhythmic medication for the treatment of&#xD;
             ventricular tachyarrhythmias&#xD;
&#xD;
          -  Women who are pregnant or with child bearing potential and who are not on a reliable&#xD;
             form of birth control&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David S. Schwartzman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC Cardiovascular Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2010</study_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>CRT-D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

